Poseida Therapeutics, Inc. financial data

Symbol
PSTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9390 Towne Centre Drive, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 282 % -38%
Debt-to-equity 236 % +121%
Return On Equity -72.3 % +16.9%
Return On Assets -21.5 % +48.8%
Operating Margin -41.4 % +84.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.5M shares +1.93%
Common Stock, Shares, Outstanding 97.4M shares +1.92%
Entity Public Float 123M USD +22.9%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 97.2M shares +5.73%
Weighted Average Number of Shares Outstanding, Diluted 98.2M shares +6.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 151M USD +203%
Research and Development Expense 172M USD +16%
General and Administrative Expense 40.9M USD +7.88%
Operating Income (Loss) -62.5M USD +54.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 20.3M USD
Income Tax Expense (Benefit) 43K USD -59.8%
Net Income (Loss) Attributable to Parent -60.8M USD +53.8%
Earnings Per Share, Basic -0.61 USD/shares +53.4%
Earnings Per Share, Diluted -0.61 USD/shares +53.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.3M USD +93.5%
Cash, Cash Equivalents, and Short-term Investments 231M USD -3.31%
Accounts Receivable, after Allowance for Credit Loss, Current 14.7M USD +70.1%
Assets, Current 251M USD -0.78%
Property, Plant and Equipment, Net 17.4M USD -14.8%
Operating Lease, Right-of-Use Asset 19.1M USD -15.6%
Intangible Assets, Net (Excluding Goodwill) 1.32M USD 0%
Goodwill 4.23M USD 0%
Other Assets, Noncurrent 905K USD -16.7%
Assets 294M USD -2.87%
Accounts Payable, Current 5.2M USD +104%
Employee-related Liabilities, Current 9.32M USD +8%
Liabilities, Current 78.3M USD +1.68%
Operating Lease, Liability, Noncurrent 17.7M USD -18.9%
Other Liabilities, Noncurrent 3.05M USD +23.2%
Liabilities 206M USD +15.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 376K USD
Retained Earnings (Accumulated Deficit) -630M USD -10.7%
Stockholders' Equity Attributable to Parent 87.2M USD -29.5%
Liabilities and Equity 294M USD -2.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.1M USD +60.2%
Net Cash Provided by (Used in) Financing Activities -43K USD -104%
Net Cash Provided by (Used in) Investing Activities 24M USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 97.4M shares +1.92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.83M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.01M USD +10.1%
Deferred Tax Assets, Valuation Allowance 201M USD +24.2%
Deferred Tax Assets, Gross 210M USD +22.4%
Operating Lease, Liability 23.8M USD -14.2%
Payments to Acquire Property, Plant, and Equipment 130K USD -83.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.2M USD +54.2%
Lessee, Operating Lease, Liability, to be Paid 29.3M USD -17.3%
Property, Plant and Equipment, Gross 40.2M USD +5.79%
Operating Lease, Liability, Current 6.09M USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.11M USD -19.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.37M USD +3.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.49M USD -28.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.26M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 91.3M USD +2.22%
Unrecognized Tax Benefits 15.3M USD +29.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.42M USD +3%
Operating Lease, Payments 1.5M USD -11.8%
Share-based Payment Arrangement, Expense 23M USD +1.84%
Interest Expense 9.07M USD -20.9%